Abstract
The gut-associated lymphoid tissues (GALT) are the largest in the body and can mount a wide array of different effector mechanisms to counter the continual challenge of potential pathogens. Mobilisation of this powerful battery of responses against food antigens would be undesirable, partly because it would limit their uptake and metabolic usefulness, but more importantly hypersensitivity to foods can produce intestinal pathology, such as that seen in coeliac disease and other food sensitive enteropathies (FSE).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Elson C, Sartor, RB, Tennyson, GS, Riddell, RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995; 109: 1344–67
Mowat AMcI. The regulation of immune responses to dietary protein antigens. Immunology Today. 1987; 8: 93–8.
Faria AMC, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999; 73: 153–264
Mowat AMcI, Weiner HL. 1999. Oral tolerance: basic mechanisms and clinical implications. In Mucosal Immunology, 2nd edition, eds. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, J. Bienenstock, San Diego: Academic Press, 587–617
Strobel S, Ferguson A. Persistence of oral tolerance in mice fed ovalbumin is different for humoral and cell mediated immune responses. Immunology. 1987; 60: 317–8.
Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO. Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. Journal of Immunology. 1994; 152: 4663–4670.
Matsui M, Hafler DA, Weiner HL. Pilot study of oral tolerance to keyhole limpet hemocyanin in humans. Down regulation of KLH-reactive precursor-cell frequency. Ann NY Acad Sci. 1996; 778: 398–404
Suko M, Mori A, Ito K, Okudaira H. Oral immunotherapy may induce T cell anergy. Int Arch Allergy Immunol. 1995; 107: 278–81
Bagot M, Charue D, Flechet ML, et al. Oral desensitization in nickel allergy induces a decrease in nickel-specific T-cells. European Journal of Dermatology. 1995; 5: 614–617
Streilein JW. Immunologic privilege of the eye. Springer Semin Immunopathol. 1999; 21: 95–111.
Miller A, Al-Sabbagh A, Santos LMB, Das MP, Weiner HL. Epitopes of myelin basic protein that trigger TGF-b release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 1993; 151: 7307–7315
Gregerson DS, Obritsch WF, Donoso LA. Oral tolerance in experimental autoimmune uveoretinitis: Distinct mechanisms of resistance are induced by low versus high dose feeding protocols. J. Immunol. 1993; 151: 5751–5761
Al-Sabbagh A, Miller A, Santos LMB, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol. 1994; 24: 2104–2109
Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J. Immunol. 1995; 155: 3653–3659
Javed NH, Gienapp IE, Cox KL, Whitacre CC. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 1995; 155: 1599–1605
Wildner G, Hünig, T. & Thurau, S.R. Orally induced, peptide-specific g/d TCR+ cells suppress experimental autoimmune uveitis. Eur J Immunol. 1996; 26: 2140–8
Hoyne GF, Callow MG, Kuo MC, Thomas WR. Inhibition of T-cell responses by feeding peptides containing major and cryptic eptopes: studies with the Der p I allergen. Immunology. 1994; 83: 190–195
Thurau SR, Diedrichs-Mohring M, Fricke H, Burchardi C, Wildner G. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett. 1999; 68: 205–12.
Elson CO, Ealding W. Generalised systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 1984; 132: 2736–2741
Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986; 59: 301–308
Wilson AD, Stokes CR, Bourne FJ. Adjuvant effect of cholera toxin on the mucosal immune response to soluble proteins. Differences between mouse strains and protein antigens. Scand. J. Immunol. 1989; 29: 739–45.
Van der Heijden PJ, Bianchi ATJ, Dol M, et al. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Immunology. 1991; 72: 89–93
McGhee JR, Mestecky J, Dertzbaugh MT, et al. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992; 10: 75–88.
GaboriauRouthiau V, Moreau M. Gut flora allows recovery of oral tolerance to ovalbumin in mice after transient breakdown mediated by cholera toxin or Escherichia coli heat-labile enterotoxin. Pediatric Research. 1996; 39: 625–629
Heppell LM, Kilshaw Pi. Immune reponses in guinea pigs to dietary protein. I. Induction of tolerance by feeding ovalbumin. Int. Archs. Allergy Appl. Immunol. 1982; 68: 54–61
Mowat AMcI, Strobel S, Drummond HE, Ferguson A. Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology. 1982; 45: 104–113
Mowat AMcI, Thomas MJ, Mackenzie S, Parrott DMV. Divergent effects of bacterial lipopolysaccharide on immunity to orally administered protein and particulate antigens in mice. Immunology. 1986; 58: 677–84.
Kay R, Ferguson A. The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity. Immunology. 1989; 66: 410–415
Ke Y, Kapp JA. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells and antibody responses while activating CD8+ suppressor T cells. J. Immunol. 1996; 156: 916–21
Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol. 1994; 12: 809–38.
Melamed D, Friedman A. In vivo tolerization of Thl lymphocytes following a single feed with ovalbumin: anergy in the absence of suppression. Eur. J. Immunol. 1994; 24: 1974–1981
Fishman-Lobell J, Friedman A, Weiner HL. Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. Eur. J. Immunol. 1994; 24: 2720–2724
Melamed D, Fischmann-Lobell J, Uni Z, Weiner HL, Friedman A. Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin. Int. Immunology.1996; 8:717–24.
von Herrath MG, Dyrberg T, Oldstone MBA. Oral insulin treatment suppresses virus-induced antigen-specific destruction of b cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest. 1996; 98: 1324–31.
Claessen AME, Von Blomberg, B.M.E., De Groot, J., Wolvers, D.A.E., Kraal, G., Scheper,R.J. Reversal of mucosal tolerance by subcutaneous administration of interleukin-12 at the site of attaepted sensitization. Immunology. 1996; 88: 363–7.
Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 1997; 159: 1739–45.
Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA. 1994; 91: 6688–6692
Garside P, Steel M, Worthey EA, et al. Th2 cells are subject to high dose oral tolerance and are not essential for its induction. J. Immunol. 1995; 154: 564–955
Chen Y, Inobe J-I, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995; 376: 177–180.
Garside P, Steel M, Liew FY, Mowat AMcI. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int. Immunol. 1995; 7: 501–4
Desvignes C, Bour H, Nicholas JF, Kaiserlian D. Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility antigen deficient mice and in CD4+ T cell-depleted mice. Eur. J. Immunol. 1996; 26: 1756–1761
Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science. 1996; 274: 1707–9.
Kim S-K, Reed DS, Olson S, et al. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc. Natl. Acad. Sci. (USA). 1998; 95: 10814–9.
Blanas E, Carbone FR, Heath WR. A bone marrow-derived APC in the gut-associated lymphoid tissue captures oral antigens and presents them to both CD4+ and CD8+ T cells. J. Immunol. 2000;: In Press
Dahlgren UIH, Wold AE, Hanson LA, Midtvedt T. Expression of dietary protein in E. coli renders it strongly antigenic to gut lymphoid tissue. Immunology. 1991; 73: 394–397
Stokes R, Newby TJ, Huntley JH, Patel D, Bourne FJ. The immune response of mice to bacterial antigens given by mouth. Immunology. 1979; 38: 497–502
Titus RG, Chiller JM., Orally-induced tolerance. Definition at the cellular level. International Archives of Allergy and Applied Immunology. 1981; 65: 323–338
Maloy KJ, Donachie AM, O’Hagan DT, Mowat AMcI. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology. 1994; 81: 661–667
Owen RL. M cells--entryways of opportunity for enteropathogens. J Exp Med. 1994; 180: 7–9
Ermak T, Dougherty, EP, Bhagat, HR, Kabok, Z, Pappo, J. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer’s patch M cells. Cell Tissue Res. 1995; 279:433–6
Jones B, Pascopella L, Falkow S. Entry of microbes into the host: using M cells to break the mucosal barrier. Curr Opin Immunol. 1995; 7: 474–8
Michalek SM, Eldridge JH, Curtiss R, III., Rosenthal KL. 1994. Antigen delivery systems: new approaches to mucosal immunization. In Handbook of Mucosal Immunology, eds. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, J. Bienenstock. San Diego, CA.: Academic Press, Inc., 373–390
Hirahara K, Hisatune T, Nishijima K-I, et al. CD4+ T cells anergized by high dose feeding establish oral tolerance to antibody responses when transferred in SCID and nude mice. J. Immunol. 1995; 154: 6238–6245
Lundin BS, Dahlgren UI, Hanson LA, Telemo E. Oral tolerization leads to active suppression and bystander tolerance in adult rats, while anergy dominates in young rats. Scand J Immunol. 1996; 43: 56–63
Lamont AG, Mowat AMcI, Parrott DMV. Priming of systemic and local delayed-type hypersensitivity responses by feeding low doses of ovalbumin to mice. Immunology. 1989; 66: 595–9.
Meyer AL, Benson JM, Gienapp IE, Cox KL, Whitacre CC. Suppression of murine chronic relapsing autoimmune encephalomyelitis by the oral administration of myelin basic protein. J. Immunol. 1996; 157: 4230–4238
Miller BG, Newby TJ, Stokes CR, Bourne FJ. Influence of diet on postweaning malabsorption and diarrhoea in the pig. Res. Vet. Sci. 1984; 36: 187–193
Jarrett EE. Perinatal influences on IgE responses. Lancet. 1984; ii: 797–799
Kiyono H, McGhee JR, Wannemuehler MJ, Michalek SM. Lack of oral tolerance in C3H/HeJ mice. J Exp Med. 1982; 155: 605–10.
Michalek SM, Kiyono H, Wannemuehler MJ, Mosteller LM, McGhee JR. Lipopolysaccharide (LPS) regulation of the immune response: LPS influence on oral tolerance induction. J. Immunol. 1982; 128: 1992–1998
Kitamura K, Kiyono H, Fujihashi K, et al. Contrasuppressor cells that breakoral tolerance are antigen-specific T cells distinct from T helper (L3T4+), Tsuppressor (Lyt2+) and B cells. J. Immunol. 1987; 139: 3251–3259
Saklayen MG, Pesce AJ, Pollak VE, Michael JG. Induction of oral tolerance in mice unresponsive to bacterial lipopolysaccharide. Infect. Immun. 1983; 41: 1383–5
Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996; 26: 934–8.
Elson C, Beagley K, Sharmanov A, et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J. Immunol. 1996; 157: 2174–85
Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282: 2085–8
Kim JH, Ohsawa M. Oral tolerance to ovalbumin in mice as a model for detecting modulators of the immunologic tolerance to a specific antigen. Biol Pharm Bull.1995; 18: 854–8.
Khoury SJ, Lider O, Al-Sabbagh A, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell. Immunol. 1990; 131: 302–310
Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor b, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 1992; 176: 1355–1364
Moreau MC, Corthier G. Effect of the gastrointestinal microflora on induction and maintenance of oral tolerance to ovalbumin in C3H/HeJ mice. Infect. Immunol. 1988; 56: 2766–2768
Moreau M, GaboriauRouthiau V. The absence of gut flora, the doses of antigen ingested and ageing affect the long-term peripheral tolerance induced by ovalbumin feeding in mice. Res. Immunol. 1996; 147: 49–59
Newberry RD, Stenson WP, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nature Medicine. 1999; 5: 900–6.
Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1995; 102: 448–455
Macpherson AJ, Maloy KJ, Bjarnason I. Intolerance of the dirty intestine. Gut. 1999; 44: 774–5
Karlsson MR, Kahu H, Hanson LA, Telemo E, Dahlgren UI. Neonatal colonization of rats induces immunological tolerance to bacterial antigens. Eur. J. Immunol. 1999; 29: 109–18
Hanson DG, Miller SD. Inhibition of specific immune responses by feeding protein antigens. V. Induction of the tolerant state in the absence of specific suppressor T cells. J. Immunol. 1982; 128: 2378–2381
Tomasi TB, Barr WG, Challacombe SJ, Curran G. Oral tolerance and accessory cell function of Peyer’s patches. Ann NY Acad Sci. 1983; 409: 145–163.
Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalitis. III. Evidence for clonal anergy. J. Immunol. 1991; 147: 2155–2163
Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur. J. Immunol. 1993; 23: 935–42
Inada S, Yoshino S, Hague MA, Ogata Y, Kohashi O. Clonal anergy is a potent mechanism of oral tolerance in the suppression of acute antigen-induced arthritis in rats by oral administration of the inducing antigen. Cell. Immunol. 1996; 175: 67–75.
Marth T, Strober W, Kelsall BL. High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralisation of interleukin 12 augments TGF(3 secretion and T cell apoptosis. J. Immunol. 1996; 157: 2348–57
Chen Y, Inobe J-I, Kuchroo VK, et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc. Natl. Acad. Sci. (USA). 1996; 93: 388–91.
Migita K, Ochi A. Induction of clonal anergy by oral administration of staphylococcal enterotoxin B. Eur. J. Immunol. 1994; 24: 2081–2086
Garside P, Steel M, Worthey EA, et al. Oral tolerance in mice is associated with increased susceptibility of challenged lymphocytes to undergo apoptosis in vivo. Am J Path. 1996; 149: 1971–80.
Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity. 1994; 1: 327–339
Sun J, Dirden-Kramer B, Ito K, Ernst PB, Van Houten N.,Antigen-specific T cell activation and proliferation during oral tolerance induction. J. Immunol. 1999; 162: 5865–75.
Van Houten N, Blake SF. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J. Immunol. 1996; 157: 1337–41
Chen Y, Inobe J-I, Weiner HL. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol. 1997; 178: 62–8.
Williamson E, O’Malley JM, Viney JL. Defining the role of dendritic cells in oral tolerance induction by visualizing the T cell response elicited by oral administration of soluble protein antigen. Immunology. 1999; 97: 565–72.
Gütgemann I, Fahrer AM, Davis MM, Chien Y-H. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. Immunity. 1998; 8: 667–73.
Neumann B, Luz A, Pfeffer K, Holzmann B. Defective Peyer’s patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J. Exp. Med. 1996; 184: 259–64.
Pape KA, Kearney ER, Khoruts A, et al. Use of adoptive transfer of T-cellantigen-receptor-transgenic T cells for the study of T-cell activation in vivo. Immunol Rev. 1997; 156: 67–78.
Perez VL, Parijs Lv, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997; 6: 411–7.
Mosmann TR, Sad S. The expanding universe of T-cell subsets: Thl, Th2, and more. Immunology Today. 1996; 17: 138–146
Grdic D, Hornquist E, Kjerrulf M, Lycke N. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J Immunol. 1998; 160: 754–62
Vistica BP, Chanaud, N.P., Felix, N., Caspi, R.R., Rizzo, I.V., Nussenblatt, R.B., Gery, I. CD8 T-cells are not essential for the induction of “low dose” oral tolerance. Clin Immunol Immunopathol. 1996; 78: 196–202
Chen Y, Inobe J-I, Weiner HL. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediate active suppression. J. Immunol. 1995; 155: 910–916
Barone KS, Jain SL, Michael JG. Effect of in vivo depletion of CD4+ and CD8+ cells on the induction and maintenance of oral tolerance. Cell. Immunol. 1995; 163: 19–29
McMenamin C, Pimm C, McKersey M, Holt PG. Regulation of IgE responses to inhaled antigen in mice by antigen-specific yδ T cells. Science. 1994; 265: 1869–71.
McMenamin C, McKersey M, Kuhnlein P, Hunig T, Holt PG. yδ T cells down-regulate primary IgE responses in rats to inhaled soluble protein antigens. J. Immunol. 1995; 154: 4390–4394
McMenamin C, Oliver J, Girn BJ, et al. Regulation of T-cell sensitization at epithelial surfaces in the respiratory tract: Suppression of IgE responses to inhaled antigens by CD3+TCRcC /ß“ lymphocytes (putative y/6 T cells). Immunology. 1991; 74: 234–239
Harrison LC, Dempsey-Collier,M., Kramer, D.R., Takahashi,K. Aerosol insulin induces regulatory CD8 76 T cells that prevent murine insulin-dependent diabetes. J Exp Med. 1996; 184:2167–74.
Seymour BWP, Gershwin LJ, Coffman RL. Aerosol-induced immunoglobulin (Ig)-E unresponsiveness to ovalbumin does not require CD8+ or T cell receptor (TCR)- y/6+ T cells or interferon (IFN)-y in a murine model of allergen sensitization. J Exp Med. 1998; 187: 721–31
Mengel J, Cardillo F, Aroeira LS, et al. Anti-gammadelta T cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Immunology Letters. 1995; 48: 97–102
Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA. yδ T lymphocytes regulate the induction of oral tolerance. J. Immunol. 1997; 158: 3610–8.
Fujihashi K, McGhee JR, Kweon M-N, et al. y/6 T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med. 1996; 183: 1929–35.
Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner I-L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994; 265: 1237–40.
Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-ß-mediated oral tolerance. J Exp Med. 1996; 183: 2605–16.
Gonnella PA, Chen Y, Inobe J-I, et al. In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR-transgenic mice. J. Immunol. 1998; 160: 4708–18.
Yoshino S. Treatment with anti-IL4 monoclonal antibody blocks suppression of collagen-induced arthritis in mice by oral administration of type II collagen. J. Immunol. 1998; 160: 3067–71.
Yoshino S, Yoshino J. Effect of a monoclonal antibody against interleukin-4 on suppression of antigen-induced arthritis in mice by oral administration of the inducing antigen. Cell. Immunol. 1998; 187: 139–44.
Wolvers DAW, van der Cammen MJF, Kraal G. Mucosal tolerance is associated with, but independent of, upregulation of Th2 responses. Immunology. 1997; 92: 328–33.
Shi HN, Grusby MJ, Nagler-Anderson C. Orally induced peripheral nonresponsiveness is maintained in the absence of functional Thl or Th2 cells. J Immunol. 1999; 162: 5143–8.
Rizzo LV, Morawetz RA, Miller-Rivero NE, et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J. Immunol. 1999; 162: 2163–22.
Fukaura H, Kent SC, Pietrusewicz ML, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-ß1secreting Th3 cells by oral administration of myelin in multiple sclerosis. J Clin Invest. 1996; 98: 70–7.
Groux H, Powrie F. Regulatory T cells in inflammatory bowel disease. Immunology Today. 1999; 20: 442–6.
Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389: 737–42.
Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-l0deficient mice develop chronic enterocolitis. Cell. 1993; 75: 263–279
Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999; 190: 995–1004
Aroeira LS, Cardillo F, De-Albuquerque D, Vaz NM, Mengel J. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand. J. Immunol. 1995; 44: 319–323
Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunology Today. 1997; 18: 335–343
Lundin BS, Karlsson MR, Svensson LA, et al. Active suppression in orally tolerized rats coincides with in situ transforming growth factor-ß (TGF-ß) expression in the draining lymph nodes. Clin Exp Immunol. 1999; 116: 181–7
Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor-13 after antigen-specific triggering. PNAS. 1992; 89: 421–425
Haneda K, Sano K, Tamura G, et al. TGF-ß induced by oral tolerance ameliorates experimental tracheal eosinophilia. J. Immunol. 1997; 159: 448–490.
Inobe J-I, Slavin AJ, Komagata Y, et al. IL-4 is a differentiation factor for transforming growth factor-b secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 1998; 28: 2780–90.
Barone KS, Tolarova DD, Ormsby I, Doetschman T, Michael JG. Induction of oral tolerance in TGF-(31 null mice. J. Immunol. 1998; 161: 154–60.
Gautam SC, Chikkala NF, Battisto JR. Oral administration of the contact sensitizer trinitrochlorobenzene: initial sensitization and subsequent appearance of a suppressor population. Cell. Immunol. 1990; 125: 437–448
Hoyne GF, Thomas WR. T-cell responses to orally administered antigens. Study of the kinetics of lymphokine production after single and multiple feeding. Immunology. 1995; 84: 304–309.
Hoyne GF, Callow MG, Kuhlman J, Thomas WR. T-cell lymphokine response to orally administered proteins during priming and unresponsiveness. Immunology. 1993; 78: 534–40
Mowat AMcI, Steel M, Leishman AJ, Garside P. Normal induction of oral tolerance in the absence of a functional IL12 dependent g interferon signalling pathway. J. Immunol. 1999; 1: 4728–36
Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol. 1989; 7: 445–480
Baschieri S, Lees RK, Lussow AR, MacDonald HR. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur. J. Immunol. 1993; 23: 2661–2666
Kjerrulf M, Grdic D, Ekman L, et al. Interferon-y-receptor-deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance. Immunology. 1997; 92: 60–8
Grdic D, Smith RE, Donachie AM, et al. The mucosal adjuvant effect of cholera toxin and ISCOMS differ in their requirement for IL-12, indicating different pathways of action. Eur J Immunol. 1999; 29: 1774–84.
Kweon M-N, Fujihashi K, VanCott JL, et al. Lack of orally induced systemic unresponsiveness in IFN-g knockout mice. J Immunol. 1998; 160: 1687–93
Lee HO, Miller SD, Hurst SD, Tan LJ, Cooper CJ, Barrett TA. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology 2000;119:129–38.
Zhang Z, Michael JG. Orally inducible immune unresponsiveness is abrogated by IFNg treatment. J. Immunol. 1990; 144: 4163–4165
Boyaka P, Marinaro M, Jackson RJ, et al. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol. 1999; 162: 122–8.
Karpus WJ, Kennedy KJ, Kunkel SL, Lukacs NW. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines. J Exp Med. 1998; 187: 733–41.
Yoshino S, Quattrocchi E, Weiner HL. Oral administration of type II collagen suppresses antigen-induced arthritis in Lewis rats. Arthritis & Rheumatism. 1995; 38: 1092–1096
Zhang JZ, Lee CSY, Lider O, Weiner HL. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J. Immunol. 1990; 145: 2489–2493
Lanzavecchia A. Licence to kill. Nature. 1998; 393: 413–4.
Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Ann Rev Immunol. 1998; 16: 619–44.
Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J. Immunol. 1998; 161: 5813–6
Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 2000; 164: 183–90.
Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998; 188: 287–96
Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science. 1994; 264: 1587–9
Taams LS, van Rensen AJML, Poeten MCM, et al. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur. J. Immunol. 1998; 28: 2902–12.
Homann D, Holz A, Bot A, et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat 6 pathway. Immunity. 1999; 11: 463–72.
Read S, Mauze S, Asseman C, et al. CD38+CD45RB1o“’CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur. J. Immunol. 1998; 28: 3435–47.
Hoyne GF, Le Roux I, Corsin-Jimenez M, et al. Serratel-induced Notch signalling regulates the decision between immunity and tolerance made by peripheral CD4(+) T cells. Int Immunol. 2000; 12: 177–185
Chai J-G, Bartok I, Chandler P, et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur. J. Immunol. 1999; 29: 686–92.
Banchereau J, Steinman RL. Dendritic cells and the control of immunity. Nature. 1998; 392: 245–52
Kopf M, Rued! C, Schmitz N, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity. 1999; 11: 699–708
Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991; 252: 1308–1310
Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Ann Rev Immunol. 1996; 14: 1–27
Buer J, Lanoue A, Franzke A, et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med. 1998; 187: 177–183
Cauley LS, Cauley KA, Shub F, Huston G, Swain SL. Transferable anergy: superantigen treatment induces CD4+ T cell tolerance that is reversible and requires CD4–CD8- cells and interferon-y. J. Exp. Med. 1997; 186: 71–81.
Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998; 10: 1969–80.
Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor-(3 (TGF-ß) production by murine CD4+ T cells. J. Exp. Med. 1998; 188: 1849–57.
Dahlman-Hoglund A, Ahlstedt S, Hanson LA, Dahlgren U, Telemo E. Different expression of IL-2 receptor alpha-chain on a lamina propria T cell population and goblet cells in rats orally tolerized or sensitized to ovalbumin (OA) after colonization with an OA-producing Escherichia coli. Clin Exp Immunol. 1996; 106: 534–40
Hanson DG, Vaz NM, Rawlings LA, Lynch JM. Inhibition of specific immune responses by feeding protein Ag’s II. Effects of prior passive and active immunisation. J. Immunol. 1979; 122: 2261–2266
Strobel S, Mowat AMcI, Drummond HE, Pickering MG, Ferguson A. Immunological responses to fed protein antigens in mice. 2. Oral tolerance for CMI is due to activation of cyclophosphamide sensitive cells by gut processed antigen. Immunology. 1983; 49: 451–6.
Bruce MG, Ferguson A. Oral tolerance to ovalbumin in mice: Studies of chemically modified and of “biologically filtered” antigen. Immunology. 1986; 57: 627–630
Bruce MG, Ferguson A. The influence of intestinal processing on the immunogenicity and molecular size of absorbed, circulating ovalbumin in mice. Immunology. 1986; 59: 295–300
Kay R, A. F. The immunological consequences of feeding cholera toxin. II. Mechanisms responsible for the induction of oral tolerance for DTH. Immunology. 1989; 66: 416–421.
Peng H-J, Turner MW, Strobel S. The generation of a ’tolerogen’ after the ingestion of ovalbumin is time-dependent and unrelated to serum levels of immunoreactive antigen. Clin. Exp. Immunol. 1990; 81: 510–15
Furrie E, Turner MW., Strobel S. Partial characterization of a circulating tolerogenic moiety which, after a feed of ovalbumin, suppresses delayed-type hypersensitivity in recipient mice. Immunology. 1995; 86: 480–6.
Karlsson M, Kahu K, Hanson LA, Dahlgren U, Telemo E. 70,000g pellet from serum transfer tolerance: role of major histocompatibility complex class II. Immunol Letters. 1999; 69: 87(A)
Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4: 594–600
Sanderson I, Ouellette, AJ, Carter, EA, Walker, WA, Harmatz, PR. Differential regulation of B7 mRNA in enterocytes and lymphoid cells. Immunology. 1993; 79: 434–8
Bloom S, Simmons, D, Jewell, DP. Adhesion molecules intercellular adhesion molecule-1 (ICAM-1), ICAM-3 and B7 are not expressed by epithelium in normal or inflamed colon. Clin Exp Immunol. 1995; 101
Dippold W, Wittig, B, Schwaeble, W, Mayet, W, Meyer zum Buschenfelde, KH. Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells. Gut. 1993; 34: 1593–7.
Furrie E, Turner MW, Strobel S. Failure of scid mice to generate an oral tolerogen after a feed of ovalbumin: a role for a functioning gut-associated lymphoid system. Immunology. 1994; 83: 562–7.
Stokes CR, Newby TJ, Bourne FJ. The influence of oral immunization on local and systemic immune responses to heterologous antigens. Clin. Exp. Immunol. 1983; 52: 399–406
Mowat AMcI, Parrott DMV. Immunological responses to fed protein antigens in mice. IV. Effects of stimulating the reticuloendothelial system on oral tolerance and intestinal immunity to ovalbumin. Immunology. 1983; 50: 547–554.
Strobel C, Mowat AMcI, Ferguson A. Prevention of oral tolerance induction to ovalbumin and enhanced antigen presentation during a graft-versus-host reaction in mice. Immunology. 1985; 56: 57–64
Strobel S, Ferguson A. Modulation of intestinal and systemic immune responses to a fed protein. Gut. 1986; 27: 829–37
Hershberg RM, Mayer LM. Antigen processing and presentation by intestinal epithelial cells - polarity and complexity. Immunology Today. 2000;In Press
Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992; 258: 1156
Buhlmann JE, Foy TM, Aruffo A, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity. 1995; 2: 645–53.
Gilbert KM, Weigle WO. B cell presentation of a tolerogenic signal to Th clones. Cell. Immunol. 1992; 139: 58–71
Jenkins MK, Burrell E, Ashwell JD. Antigen presentation by resting B cells. Effectiveness at inducing T cell proliferation is determined by costimulatory signals, not T cell receptor occupancy. J. Immunol. 1990; 144: 1585–90
D’Orazio TJ, Niederkorn JY. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology. 1998; 95: 47–55
Yoshida H, Hachimura S, Hirahara K, et al. Induction of oral tolerance in splenocyte-reconstituted SCID mice. Clin Immunol Immunopathol. 1998; 87: 282–91.
Viney JL, Mowat AMcI, O’Malley JM, Williamson E, Fanger N. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 1998; 160: 5815–25.
Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 1999; 163: 3668–75.
Iwasaki A, Kelsall BL. Freshly isolated Peyer’s patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 1999; 190: 229–39
Stumbles PA, Thomas JA, Pimm CL, et al. Resting respiratory tract dendritic cells preferentially stimulate helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Thl immunity. J. Exp. Med. 1998; 188: 2019–31.
Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunology Today. 1999; 20
Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998; 58: 1208–16
Schwartz RH. T cell clonal anergy. Curr Opinion in Immunology. 1997; 9: 351–7.
Pape KA, Merica R, Mondino A, Khoruts A, Jenkins MK. Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J Immunol. 1998; 160: 4719–29.
Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-y and TGF-ß responses regulate the occurrence of mucosal inflammation. Immunology Today. 1997; 18: 61–4.
Samoilova EB, Horton JL, Zhang H, et al. CTLA-4 is required for the induction of high dose oral tolerance. Int. Immunology. 1998; 10: 491–8.
Oosterwegel MA, Greenwald RI, Mandelbrot DA, Lorsbach RB, Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol. 1999; 11: 294–300.
Kuchroo VK, Das JA, Brown AM, et al. B7–1 and B7–2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995; 80: 707–718
Schweitzer AN, Borriello F, Wong RC, Abbas AK, Sharpe AH. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol. 1997; 158: 2713–22.
Kweon M-N, Fujihashi K, Wakatsuki Y, et al. Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand - CD40 interactions. J. Immunol. 1999; 162: 1904–9.
Liu L, MacPherson G. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J. Exp. Med. 1993; 177: 1299–307
Liu L, MacPherson, GG. Rat intestinal dendritic cells: immunostimulatory potency and phenotypic characterization. Immunology. 1995; 85: 88–93
MacPherson G, Jenkins, CD, Stein, MJ, Edwards, C. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence. J. Immunol. 1995; 154: 1317–22.
Harper H, Cochrane, L, Williams, NA. The role of small intestinal antigen-presenting cells in the induction of T-cell reactivity to soluble protein antigens: association between aberrant presentation in the lamina propria and oral tolerance. Immunology. 1996; 89.: 449–56
Kelsall B, Strober W. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer’s patch. J Exp Med. 1996; 183: 237–47
Ruedl C, Hubele S. Maturation of Peyer’s patch dendritic cells in vitro upon stimulation via cytokines or CD40 triggering. Eur. J. Immunol. 1997; 27: 1325–30
Spahn TW, Koni PA, Marino MW, et al. A critical role for the gut-associated lymphatic tissue in the induction of oral tolerance. Immunol Letters. 1999; 69: 86
Wolvers DAW, Coenen-De Roo CJJ, Mebius RE, et al. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp39. J. Immunol. 1999; 162: 1994–8.
Mowat AMcI, Viney JL. The anatomical basis of mucosal immune responses. Immunol. Rev. 1997; 156: 145–66.
Mowat AMcI. 1999. Induction of peripheral tolerance by portal vein administration of antigen. In The Immunology of the Liver, ed. I. N. Crispe, 101–15. New York: John Wiley & Sons Inc.
Gorczynski RM, Chen Z, Zeng H, Fu XM. Specificity for in vivo graft prolongation in yS T cell receptor hybridomas derived from mice given portal vein donor-specific preimmunization and skin allografts. J. Immunol. 1997; 159: 3698–3706.
Teng Y-T, Gorczynski RM, Hozumi N. Function of TGF-ß-mediated innocent bystander suppression associated with physiological self-tolerance in vivo. Cell. Immunol. 1998; 190: 51–60.
Yang R, Liu Q, Grosfeld JL, Pescovitz MD. Intestinal drainage through liver is a pre-requisite for oral tolerance induction. J Paediatr Surg. 1994; 29: 1145–8.
Thomas HC, Ryan CJ, Benjamin IS, Blumgart LH, MacSween RNM. The immune system response in cirrhotic rats. The induction of tolerance to orally administered protein antigens. Gastroenterology. 1976; 71: 114–117
Thomson AW, Drakes ML, Zahorchak AF, et al. Hepatic dendritic cells: immunobiology and role in liver transplantation. J Leukoc Biol. 1999; 66: 322–30
Lafont S, Andre C, Andre F, Gillon J, Fargier MC. Abrogation by subsequent feeding of antibody response, including IgE in parenterally immunised mice. J. Exp. Med. 1982; 155: 1573–1578
Higgins PJ, Weiner H. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 1988; 140: 440–445
Lider O, Santos LMB, Lee CSY, Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. J. Immunol. 1989; 142: 748–52.
Lamont AG, Bruce MG, Watret KC, Ferguson A. Suppression of an established DTH response to ovalbumin in mice by feeding antigen after immunization. Immunology. 1988; 64: 135–40.
Peng HJ, Turner MW, Strobel S. The kinetics of oral hyposensitisation to a protein antigen are determined by immune status and the timing, dose and frequency of antigen administration. Immunology. 1989; 67: 425–30.
Thompson HS, Staines NA. Could specific oral tolerance be a therapy for utoimmune disease? Immunology Today. 1990; 11: 396–399
Melamed D, Friedman A. Modification of the immune response by oral tolerance: antigen requirements and interaction with immunogenic stimuli. Cell Immunol. 1993; 146: 412–20.
Hirahara K, Saitom S., Serizawa N, et al. Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific Th1 and Th2 cell responses in cryj2-primed mice. J Allergy Clin Immunol. 1998; 102: 961–7.
Leishman AJ, Garside P, Mowat AMcI. Intervention in established immune responses by induction of oral tolerance. Cell. Immunol. 1998; 183: 137–48.
Chung Y, Chang S-Y, Kang C-Y. Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. J. Immunol. 1999; 163: 3692–8.
Benson JM, Stuckman SS, Cox KL, et al. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J. Immunol. 1999; 162: 624754.
Sayegh MH, Zhang ZJ, Hancock WW, et al. Down-regulation of the immune response to histocompatibility antigen and prevention of sensitization by skin allografts by orally administered alloantigen. Transplantation. 1992; 53: 163–166
Sayegh MH, Khoury SJ, Hancock WH, Weiner HL, Carpenter CB. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc. Natl. Acad. Sci. (USA). 1992; 89: 7762–6.
He YG, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation. 1996; 61: 920–926
Nakao A, Kasai M, Kumano K, et al. High-dose oral tolerance prevents antigen-induced eosinophil recruitment into the mouse airways. Int. Immunol. 1998; 104: 387–94.
Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of tolerization with myelin antigens in multiple sclerosis. Science. 1993; 259: 1321–4.
Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of collagen on rheumatoid arthritis. Science. 1993; 261: 1727–1730
Sieper J, Kary S, Sörensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double blind, placebo-controlled, randomized trial. Arthritis and Rheumatism. 1996; 39: 41–51.
Trentham DE. Oral tolerization as a treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 1998; 24: 525–36
Hauselmann HJ, Caravatti M, Seifert B, et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol. 1998; 37: 1110–7
McKown KM, Carbone LD, Kaplan SB, et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 1999; 42: 1204–8
Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis & Rheumatism. 1996; 39: 623–628
Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998; 41: 290–7
Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am J Ophthalm. 1997; 123: 583–592
Ma S-W, Zhao D-L, Mukherjee R, et al. Transgenic plants expressing autoantigens fed to mice to induce oral tolerance. Nature Medicine. 1997; 3: 793–6.
Rizzo LV, Miller-Rivero NE, Chan C-C, et al. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest. 1994; 94: 1668–1672
Elson CO, Dertzbaugh MT. 1999. Mucosal Adjuvants. In Mucosa! Immunology,2nd Edition, eds. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, J. Bienenstock. San Diego: Academic Press, 818–38.
McGhee JR, Czerkinsky C, Mestecky J. 1999. Mucosal vaccines: an overview. In Mucosa! immunology,2nd edition, eds. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, J. Bienenstock. San Diego: Acadmeic Press, 741–57.
Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. (USA). 1994; 91: 10795–10799.
Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. (USA). 1996; 93: 7196–7201
Bergerot I, Fioix C, Peterson J, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. (USA). 1997; 94: 4610–4614
Czerkinsky C, Anjuere F, McGhee JR, et al. Mucosal immunity and tolerance: Relevance to vaccine development. Immunol. Rev. 1999; 170: 197–222
Williams NA, Hirst TR, Nashar TO. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunology Today. 1999; 20: 95–101
McSorley SJ, Rask C, Pichot R, et al. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur J Immunol. 1998; 28: 424–432.
Ploix C, Bergerot I, Durand A, et al. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes. 1999; 48: 2150–6
Mowat AMcI, Ferguson A. Hypersensitivity in the small intestinal mucosa. V. Induction of cell mediated immunity to a dietary antigen. Clin Exp Immunol. 1981; 43: 574–82.
Mowat AMcI. Depletion of suppressor T cells by 2’-deoxyguanosine abrogates tolerance in mice fed ovalbumin and permits the induction of intestinal delayed-type-hypersensitivity. Immunology. 1986; 58: 179–184
Stokes CR, Miller BG, Bourne FJ. 1987. Animal models of food sensitivity. In Food Allergy and Intolerance, ed. J. Brostoff, Challacombe, S.J., 286–300. Eastbourne, UK: W.B. Saunders
Mowat AMcI. 1984. The immunopathogenesis of food sensitive enteropathies. In Local Immune Responses of the Gut., eds. T. J. Newby, C. R. Stokes, 199–225. Boca Raton: CRC Press
Ferguson A. 1987. Models of immunologically-driven small intestinal damage. In Immunopathology of the Small Intestine, ed. M. N. Marsh, 225–252. Chichester: John Wiley and Sons
Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev. 1999; 169: 195–207
Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-b but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J exp Med. 1996; 183: 2669–74
Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to IL-12 abrogate established experimental colitis in mice. J. Exp. Med. 1995; 182: 1281–1290.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Kluwer Academic Publishers
About this chapter
Cite this chapter
Mowat, A.M. (2001). Regulation of intestinal immune responses to local antigens: oral tolerance vs immunopathology. In: Mahida, Y.R. (eds) Immunological Aspects of Gastroenterology. Immunology and Medicine Series, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0790-0_11
Download citation
DOI: https://doi.org/10.1007/978-94-010-0790-0_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-3852-2
Online ISBN: 978-94-010-0790-0
eBook Packages: Springer Book Archive